Lymphatic vessels: new targets for the treatment of inflammatory diseases by Dieterich, Lothar et al.
ORIGINAL PAPER
Lymphatic vessels: new targets for the treatment of inflammatory
diseases
Lothar C. Dieterich • Catharina D. Seidel •
Michael Detmar
Received: 28 August 2013 / Accepted: 30 October 2013 / Published online: 9 November 2013
 Springer Science+Business Media Dordrecht 2013
Abstract The lymphatic system plays an important role
in the physiological control of the tissue fluid balance and
in the initiation of immune responses. Recent studies have
shown that lymphangiogenesis, the growth of new lym-
phatic vessels and/or the expansion of existing lymphatic
vessels, is a characteristic feature of acute inflammatory
reactions and of chronic inflammatory diseases. In these
conditions, lymphatic vessel expansion occurs at the tissue
level but also within the draining lymph nodes. Surpris-
ingly, activation of lymphatic vessel function by delivery
of vascular endothelial growth factor-C exerts anti-
inflammatory effects in several models of cutaneous and
joint inflammation. These effects are likely mediated by
enhanced drainage of extravasated fluid and inflammatory
cells, but also by lymphatic vessel-mediated modulation of
immune responses. Although some of the underlying
mechanisms are just beginning to be identified, lymphatic
vessels have emerged as important targets for the devel-
opment of new therapeutic strategies to treat inflammatory
conditions. In this context, it is of great interest that some
of the currently used anti-inflammatory drugs also potently
activate lymphatic vessels.
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Introduction
The lymphatic system is closely connected to inflammatory
processes and immune functions. One of its major func-
tions is the transport of immune cells and soluble antigens
from the periphery to the lymph nodes, which are the
primary sites for activation of immune responses. Corre-
spondingly, lymphatic vessels can be found in most organs
and their network is particularly dense in the skin and near
mucosal surfaces, the main entry sites for foreign material
and pathogens into the body [1, 2]. It is thus surprising that
lymphatic vessels have been thought for decades to merely
represent a passive drainage system without any active role
in disease processes. However, recent findings indicate that
lymphatic vessels are dynamic structures that sensibly react
to inflammatory stimuli and that are activated, both at the
level of the peripheral inflamed tissue and within the
draining lymph nodes. In this review, we highlight the
capacity of lymphatic vessels to regulate inflammation
resolution and to modulate immune responses and toler-
ance, with a focus on therapeutic approaches to target
lymphatic vessels for the treatment of inflammatory
conditions.
Molecular markers of lymphatic endothelium and their
modulation in inflammation
The dramatic progress in our understanding of the active
role of lymphatic vessels in development, physiology and
disease is due to the identification of lymphatic endothelial
cell (LEC)-specific markers [3], in particular vascular
endothelial growth factor receptor (VEGFR)-3, Prox1,
LYVE-1 and podoplanin. These LEC markers allow for the
specific staining of LECs in tissue sections, their specific
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isolation in vitro and ex vivo and, subsequently, the char-
acterization of differentially expressed genes and proteins
in LECs versus blood vascular endothelial cells (BECs)
[4–7].
VEGFR-3 is a receptor tyrosine kinase for the lymph-
angiogenic growth factors VEGF-C and -D and is crucial
for growth, survival and migration of LECs [8, 9]. During
embryonic development, VEGFR-3 is expressed on both
blood vessels and on lymphatic vessels (LVs), whereas it is
mostly expressed by LECs in healthy adult tissue [10].
Some VEGFR-3 expression has been found on blood
capillaries in the spleen, kidney, and glands of the endo-
crine system [11]. Prox1 is required for the development of
the lymphatic system [12] and plays a major role as master
transcription factor responsible for LEC differentiation—
ectopic Prox1 expression partially reprograms cultured
BECs to a LEC-like phenotype [7, 13]. LYVE-1, a
homolog of the CD44 glycoprotein, is a hyaluronan
receptor of yet unclarified function that is predominantly
expressed by LECs in adult tissues [14, 15]. LYVE-1
expression is high in lymphatic capillaries but very low in
collecting LVs [16]. LYVE-1 is only rarely seen on blood
vessels, such as sinusoidal endothelial [14, 17]. Podoplanin
is a membrane glycoprotein that is expressed by LECs but
not BECs [18] and that plays a major role in normal
lymphatic development [19]. While its expression is high
on LECs of lymphatic capillaries, some LECs in lymphatic
pre-collectors show low podoplanin expression [20].
Although these markers allow the distinction of LECs
from BECs in most tissues, some non-endothelial expres-
sion has been observed. For instance, VEGFR-3 has been
found to be expressed by corneal DCs [21] and epithelium
[22], and Prox1 is expressed in liver, pancreas [23] and the
brain [24, 25]. Moreover, strong LYVE-1 expression has
been observed on a subset of macrophages in various tis-
sues, which makes it essential to distinguish them from
LVs on tissue sections [26–28]. Podoplanin is also
expressed in the choroid plexus of the brain [29, 30],
alveolar type I epithelial cells in the lung [29, 31], ciliary
epithelia of the intestine [29], stromal cells of lymphoid
organs such as the spleen [32] and LNs [33], possibly
leukocyte subsets including macrophages [34, 35] and
Th17 cells [36], nerve fibers and bile duct associated
mesenchymal cells in the liver [37]. Therefore, it is rec-
ommended to use combinations of two different lymphatic
markers or a combination of a lymphatic marker with a
pan-endothelial marker such as CD31 [38] for the unam-
biguous detection of lymphatic vessels.
Despite their usefulness for the identification of lym-
phatic vessels in normal tissues, the expression of these
lymphatic markers can be strongly modulated during
tumorigenesis [39] and inflammation, and these changes
are likely stimulus- and species-specific. In general, the
expression of most LEC markers appears to be down-reg-
ulated on lymphatic vessels during inflammation, whereas
upregulation of LEC markers by inflammatory stimuli has
been observed in BECs, at least under culture conditions
[40]. Importantly, LYVE-1 was found to be down-regu-
lated on LECs during chronic airway inflammation in vivo
[41] and also on cultured LECs upon inflammatory stimuli
[42]. Lower mRNA levels of VEGFR-3, LYVE-1 and
Prox1 and reduced podoplanin protein expression were
found on cutaneous LECs during contact hypersensitivity-
induced inflammation in mice but not by complete Fre-
und‘s adjuvant-induced inflammation [43]. Our own stud-
ies in acute skin inflammation models recently also
revealed inflammation-mediated down-regulation of
VEGFR-3 on LECs [44] whereas up-regulation of VEGFR-
3 and Prox-1 on LECs was found in a peritonitis model,
possibly mediated by nuclear factor-kappaB activation
[45]. Together, these studies highlight the stimulus-
dependent response of LECs with regard to marker
expression, and they indicate that at least two different
LEC markers should be used to investigate the response of
lymphatic vessels in inflammation.
Lymphatic vessels expansion in inflammation
Expansion of the lymphatic vascular network has been
observed in several inflammatory conditions, both in
experimental mouse models and in human inflammatory
diseases (reviewed in [46]). This expansion includes dila-
tion of pre-existing vessels (lymphatic hyperplasia) as well
as induction of lymphatic sprouting (lymphangiogenesis)
and the growth of new lymphatic vessels, resulting in an
increased lymphatic vascular density. Our laboratory
identified enlargement of lymphatic vessels in the skin of
patients suffering from psoriasis, a chronic inflammatory
skin disease, as well as in a mouse model of psoriasis [47].
In this model, transgenic mice with skin-specific overex-
pression of VEGF-A develop a chronic, psoriasis-like skin
inflammation after treatment with the contact sensitizer
oxazolone, associated with angiogenesis and with lym-
phatic vessel expansion (Fig. 1 a, b). Similarly, lymphatic
expansion has been observed in clinical samples and mouse
models of arthritis [48–50], atopic dermatitis [51] and
inflammatory bowel disease [52, 53].
It is currently a matter of debate whether the inflam-
mation (or growth factor)-induced lymphatic vessel
expansion might be reversible or not. After adenoviral
delivery of VEGF-A to mouse ears, expanded and func-
tionally impaired lymphatic vessels persisted for many
months whereas angiogenic blood vessels regressed [54],
and chronic airway inflammation-induced lymphatic
hyperplasia persisted for an extended period of time even
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after inflammatory resolution [41]. In contrast, inflamma-
tion-induced lymphatic expansion regressed after several
months in an experimental skin inflammation model [55]
and in suture-induced inflammation in the mouse cornea
where lymphatic vessels expanded faster, however, upon
re-challenge [56]. Clearly, further research is warranted to
investigate the dynamics of lymphatic networks expansion
in different types of inflammation.
Lymph node lymphangiogenesis
In 2005, studies from our laboratory revealed that solid
tumors can induce lymphangiogenesis within their draining
lymph nodes (‘‘lymph node lymphangiogenesis’’), even
before they actually metastasize to these lymph nodes [57].
Shortly thereafter, it became clear that lymph node (LN)
lymphangiogenesis also occurs in those lymph nodes that
Fig. 1 Microscopic images of LYVE-1? lymphatic vessels (green)
and Meca32-positive blood vessels (red) in healthy mouse ear skin
a and in chronically inflamed ear skin of the K14-VEGF-A mouse
psoriasis model b. Note the tissue swelling and the enlargement and
of lymphatic vessels in inflammation. c Lymphatic vasculature
stained for LYVE-1 (green) and Prox-1 (red) in the auricular lymph
node of a healthy mouse. d Expansion of the lymphatic vascular
network in the auricular lymph node at day 7 after induction of ear
skin inflammation. Nuclei are stained in blue. Bars = 100 lm. (Color
figure online)
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drain inflammatory sites, in particular inflamed skin [58,
59] (Fig. 1 C, D). This lymphatic expansion may be
mediated by VEGF family members and other lymphan-
giogenic factors released by cells within the LN, such as B
cells [58] or macrophages [60], as well as by factors
released at the site of inflammation and subsequently
drained to the LN [59]. The relative contribution of locally
produced versus peripherally produced mediators towards
the expansion of lymphatic vessels within LNs appears to
depend on the experimental model. It is of interest that
interferon-gamma producing T lymphocytes have been
found to inhibit LN lymphangiogenesis [61] and that
inflammatory LN lymphangiogenesis was reversible in a
skin inflammation model [55].
Mediators of inflammatory lymphatic vessel expansion
VEGF-C represents the best characterized inducer of
inflammatory lymphangiogenesis, acting via binding to
VEGFR-3 and neuropilin-2 [9] and—after proteolytic
cleavage—to VEGFR-2 that is also expressed by lymphatic
endothelial cells [62]. Whereas the effects of the lymph-
angiogenic factor VEGF-D in inflammation are at present
less well studied, VEGF-A has emerged as a major
activator of inflammatory lymphatic vessel expansion
within the peripheral inflamed tissue as well as within the
draining lymph nodes [47, 54, 58, 59, 62, 63]. These effects
are likely mediated both directly, via activation of VEGFR-
2 on LECs, and indirectly via recruitment of inflammatory
cells and activation of VEGF-C production by blood ves-
sels. Macrophages appear to represent the major source of
VEGFs in inflammation [60], but other inflammatory and
resident cells likely contribute as well [58]. The major
stimuli of VEGF production in inflammation are inflam-
matory mediators and hypoxic tissue conditions [64].
Several other growth factors have been implicated in the
mediation of lymphangiogenesis, including angiopoietins 1
and 2 [65, 66], fibroblast growth factors [67, 68], hepato-
cyte growth factor [69], platelet-derived growth factors
[70], and insulin-like growth factors [71]. Their relative
contribution to inflammatory lymphatic vessel expansion
remains at present unclear (Fig. 2).
There is increasing evidence that macrophages play a
major role in lymphangiogenesis in general, and in par-
ticular in inflammatory lymphangiogenesis, via secretion of
lymphangiogenic factors [60, 72, 73]. Thus, a large number
of mediators that recruit macrophages/myeloid-derived
cells to inflamed tissues have been implicated in the indi-
rect promotion of lymphatic vessel expansion including IL-
Fig. 2 Schematic overview of the lymphangiogenic process during
inflammation. Lymphangiogenic factors produced in the inflamed
stroma directly act on local lymphatic vessels and induce sprouting
and vessel dilation 1. Inflammatory factors may directly stimulate
lymphatic vessel expansion 2. Inflammatory factors also act on local
blood vessels and mediate the recruitment of macrophages which
express lymphangiogenic growth factors such as VEGF-C 3. Inflam-
matory factors may directly induce transcription of lymphangiogenic
factors in immune cells and other stromal cells in the inflamed tissue
4. Lymph node lymphangiogenesis is induced by factors drained from
the site of inflammation and also by factors produced locally by
lymph node resident cells 5
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1b [74, 75], IL-4 [51], and CSF-1 [76]. In addition,
inflammatory mediators were found to directly stimulate
the production of VEGF-C by resident cells such as
synoviocytes [77]. Some inflammatory factors likely
stimulate LECs directly. However, due to the pleiotropic
nature of these mediators, these effects are difficult to
investigate in vivo. Consequently, direct effects of
inflammatory factors on lymphangiogenesis have mostly
been described in vitro, using proliferation, migration, or
tube formation assays with cultured LECs. Such assays
cannot reproduce the whole complexity and cellular
interactions during inflammatory lymphangiogenesis
in vivo, and it is therefore not surprising that results
obtained in vitro do not always coincide with observations
made in vivo. One example is IL-1b, which has been found
to stimulate lymphangiogenesis in vivo but to inhibit LEC
tube formation in vitro [74, 78]. A detailed list of inflam-
matory cytokines and chemokines and their known activi-
ties on lymphatic endothelial cells in vitro and
lymphangiogenesis in vivo is provided in Table 1.
Lymphatic drainage function in inflammation
It has been a topic of great dispute whether and how the
lymphatic drainage function is affected in acute and
chronic inflammatory conditions. Recently developed
in vivo imaging techniques and newly developed dyes and
tracers have helped to investigate this issue. There is strong
evidence that inflammation-draining lymphatic vessels are
hyperpermeable and drain less well, as found in a mouse
psoriasis model with transgenic VEGF-A overexpression in
the skin [47] and after acute or chronic UVB irradiation of
the skin [79]. Whereas LPS (lipopolysaccharide)-induced
peritonitis was associated with impaired lymphatic drain-
age in the diaphragm [73], acute skin inflammation induced
by LPS was associated with increased lymphatic flow [60].
In the K/BxN mouse model of arthritis, which is dependent
on a T cell mediated immune response against an auto-
antigen, an initial increase in lymphatic flow during the
acute phase was followed by an increase in lymphangio-
genesis but a decrease in lymphatic flow during the chronic
phase [80]. Similarly, in the TNF-a transgenic model, in
which arthritis develops independently of a specific
immune response, lymphatic drainage from the inflamed
paws was reported to be reduced in the chronic disease
phase of the disease [81]. However, the same group
reported increased drainage from popliteal lymph nodes in
the same model [82]. Thus, there is a need for the stan-
dardization and quantification of methods applied for
measuring lymph flow in vivo.
VEGF-A appears to be a mediator of the lymphatic
dysfunction in inflammation. VEGF-A expression is
consistently increased in inflammatory dieseases, and
adenoviral delivery of VEGF-A to the skin resulted in
enlarged, functionally abnormal LVs with delayed lym-
phatic clearance [54]. K14-VEGF-A transgenic mice,
which over-express VEGF-A in the skin, develop a psori-
asis-like inflammation with enlarged and leaky LVs [47,
83]. In UVB-irradiation studies, VEGF-A overexpression
resulted in increased skin inflammation and lymphatic
dysfunction, whereas blockade of VEGF-A signaling pre-
vented UVB-induced LV enlargement and hyperperme-
ability, edema formation and inflammation [79, 84]. Our
own recent studies indicate that lymphatic vessel drainage
function might be less affected during acute skin inflam-
mation but becomes severly impaired under chronic
inflammatory conditions [44]. Overall, the increased blood
vascular permeability in chronically inflamed tissues, often
mediated by VEGF-A, appears to be associated with
decreased lymphatic fluid drainage, often also mediated by
VEGF-A, promoting edema formation and reduced drain-
age of inflammatory mediators from the infamed site.
Activation of lymphatic vessel function inhibits
inflammation
It has been a matter of debate whether lymphatic vessels
contribute to inflammatory processes—via transport of
immune cells towards the lymph nodes and secretion of
inflammatory chemokines—or whether they might con-
tribute to inflammation resolution—via drainage of
inflammatory cells, mediators and fluids away from the
inflamed tissue. Our laboratory has recently found that
activation of lymphatic vessels via transgenic overexpres-
sion of VEGF-C or VEGF-D in the skin leads not only to
an expanded lymphatic network with enhanced fluid
drainage, but also to a potent inhibition of acute and
chronic skin inflammation [44, 63]. In accordance with
these findings, viral delivery of VEGF-C increased lym-
phangiogenesis and lymphatic flow, and also reduced the
severity of joint lesions in a model of chronic inflammatory
arthritis [81]. Importantly, intradermal injection of the
VEGFR-3 specific mutant VEGF-C156S inhibited UVB
irradiation-induced lymphatic impairment, edema forma-
tion and inflammation in the skin [85], indicating potential
therapeutic applications. In agreement with these thera-
peutic results, blockade of VEGFR-3 resulted in function-
ally impaired LVs with decreased drainage, enhanced
edema, increased inflammatory cell infiltration and pro-
longed inflammation in models of UVB irradiation-induced
skin inflammation, psoriasis, chronic airway inflammation,
chronic inflammatory arthritis and bacterial pathogen-
induced acute inflammation [41, 60, 63, 82, 86], as well as
in prolonged inflammation in experimental inflammatory
Angiogenesis (2014) 17:359–371 363
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Table 1 Pro-inflammatory factors involved in lymphangiogenesis and lymphatic hyperplasia
Factor Model Effect Mode of action References
TLR ligands
LPS Intraperitoneal/intradermal injection Lymphangiogenesis
(?)
Recruitment of macrophages [60, 72, 73]
TNF family
TNF-a Chronic M.pulmonis infection Lymphangiogenesis
(?)
Recruitment of inflammatory
cells, induction of VEGF-C
[115]
In vitro stimulation of primary synoviocytes Lymphangiogenic
factors (?)
Induction of VEGF-C in
synoviocytes
[77]
In vitro LEC tube formation Tube formation (-) Direct effect [78]
Interleukins
IL-1b IL-1b over-expression in trachea Lymphangiogenesis
(?)
Recruitment of macrophages [74]
Corneal lymphangiogenesis Lymphangiogenesis
(?)
Recruitment of macrophages [75]
In vitro LEC tube formation Tube formation (-) Direct effect [78]
IL-4 IL-4 driven atopic dermatitis Lymphangiogenesis
(?)
Recruitment of macrophages [51]
IL-6 In vitro stimulation of OSCC cells Lymphangiogenic
factors (?)
Induction of VEGF-C in OSCC
cells
[112]
In vitro LEC tube formation Tube formation (?) Direct effect [116]
IL-17 In vitro stimulation of NSCLC cells Lymphangiogenic
factors (?)
Induction of VEGF-C in
NSCLC cells
[117]
Corneal lymphangiogenesis Lymphangiogenesis
(?)
Induction of VEGF-C and –D
in the cornea
[118]
Colony stimulating factors
CSF-1 (M-CSF) Tumor lymphangiogenesis Lymphangiogenesis
(?)
Recruitment of macrophages [76]
CSF-2 (GM-CSF) In vitro LEC tube formation Tube formation (?) Direct effect [116]
Interferons
INF-c LPS/ConA induced skin inflammation
In vitro LEC sprouting and
tube formation
Lymphangiogenesis
(-) Sprouting (-)
Direct effect [61]
Tube formation (-) Direct effect [78]
Chemokines
CCL19 Diffuse alveolar damage Lymphangiogenesis
(?)
Recruitment of macrophages [119]
CXCL8 (IL-8) In vitro LEC tube formation Tube formation (?) Direct effect [100]
In vitro LEC tube formation, Matrigel plug
assay, cornea micropocket assay
Lymphangiogenesis,
tube formation (?)
Direct effect [101]
CXCL12 (SDF-1) In vitro LEC tube formation, matrigel plug
assay
Lymphangiogenesis,
tube formation (?)
Direct effect [120]
Other factors
Prostaglandin E2
(PGE2)
In vitro stimulation of lung adenocarcinoma
cells
Lymphangiogenic
factors (?)
Induction of VEGF-C in lung
adenocarcinoma cells
[121]
Matrigel plug assay Lymphangiogenesis
(?)
Induction of VEGF-C and -D [122]
Nitric oxide (NO) In vitro LEC tube formation, UVB induced
inflammation
Tube formation (?),
hyperplasia (?)
Direct effect [123]
In vitro LEC proliferation Proliferation (?),
hyperplasia (?)
Direct effect [124]
OSCC oral squamous cell carcinoma, NSCLC non-small-cell lung cancer
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bowel disease [87]. Overall, these studies clearly indicate
that promotion of lymphatic drainage by an expanded
functional lymphatic network might represent a new ther-
apeutic strategy to treat inflammatory diseases.
Modulation of inflammation and immune responses
by lymphatic vessels
In addition to the increased drainage function, activation of
lymphatic vessels by VEGF-C and other mediators might
also induce additional anti-inflammatory mechanisms [88].
While it is beyond the scope of this review to provide a
detailed discussion of the various effects of LECs on the
immune system, it is important to note that LECs are not
only involved in dendritic cell (DC) and lymphocyte traf-
ficking from the periphery to the lymph nodes, but also in
regulating lymphocyte egress from lymph nodes, immune
cell maturation and tolerance.
Upon inflammation, the chemokine-scavenging receptor
D6, an essential regulator of inflammatory leukocyte
interactions with LECs, is up-regulated on LECs. D6 binds
all inflammatory CC-chemokines but not homeostatic
chemokines such as CCL21, followed by internalization
and degradation, which prevents inappropriate adhesion of
inflammatory leukocytes and immature DCs to LECs [89].
D6 is also expressed by mucosal LECs where it controls
intestinal inflammation [90]. Furthermore, LECs are the
sole source of sphingosine-1-phosphate (S1P) in the LN
[88], which is essential to release activated lymphocytes
from LNs, while egress of naı¨ve lymphocytes is transiently
blocked during inflammation [91]. Importantly, during
prolonged inflammation, VEGF-A-induced LN lymphan-
giogenesis was recently found to restore lymphocyte egress
from LNs independently of their activation status [92].
LECs may also directly modulate the maturation of
immune cells. Recent studies found that LN stromal cell
populations, among them LECs, limit DC-induced prolif-
eration of T cells to control the expansion of activated T
cells within the LN [93, 94]. Moreover, LECs seem to
suppress DC maturation and function in inflamed tissue
[95]. This suppression was active only in the absence of
pathogen-derived signals and might thus provide a rela-
tively unspecific peripheral tolerance mechanism during
inflammation.
Diverse LN stromal cell types, among them LECs, can
act as antigen presenting cells. They express a character-
istic set of peripheral tissue antigens, controlled by an
unknown, autoimmune regulator (Aire)-independent
mechanism [96]. LN LECs present peripheral tissue anti-
gens on MHC-I, leading to deletion of self-reactive CD8 T
cells [96, 97]. This LEC-mediated deletion of self-reactive
T cells requires two interdependent pathways: a lack of
costimulation and provision of the inhibitory molecule PD-
L1. Lack of costimulation leads to an up-regulation of PD-
1 on CD8 T cells, further enhancing inhibition via the PD-
L1/PD-1 pathway. Confirming the importance of both
pathways, peripheral tissue antigen presentation by LECs
together with PD-L1 blockade or exogenous costimulation
lead to the development of autoimmune disease [98]. In
contrast to DCs, LECs up-regulate the inhibitory molecule
PD-L1 upon TLR3 stimulation, suggesting a tolerogenic
function of LECs even during exposure to danger signals
[97].
Lymphatic vasculature as a new therapeutic target
Much progress has been made with regard to inhibiting
tumor-associated lymphangiogenesis and metastasis by
targeting the VEGF-C/VEGF-D/VEGFR-3 axis. The cur-
rently evaluated drugs include anti-VEGFR-3 antibodies,
anti-VEGF-C or -D antibodies, as well as antibodies
against neuropilin-2, and at least one of them, a mono-
clonal antibody against VEGFR-3 (IMC-3C5, ImClone
Systems) has recently entered clinical testing [99]. In
contrast, with regard to inflammatory diseases, lymphatic
vessel function should most likely be therapeutically
enhanced, based on the findings discussed above. While the
direct intradermal injection of VEGF-C protein has shown
efficacy in preclinical skin inflammation models [63, 85],
this approach does not seem feasible for the treatment of
human diseases. Similar restrictions might apply to the
reported use of viral vectors to deliver VEGF-C [2], cell
based therapies [100] and application of interleukin-8
[101], since sufficient site-specific delivery of these agents
represents a major challenge, in addition to safety aspects.
It is of interest, however, that several established anti-
inflammatory drugs have been recently found to also affect
lymphangiogenesis. In particular, all-trans-retinoic acid
was identified to play a major role during embryonic
lymphatic development, and 9-cis retinoic acid was shown
to promote lymphangiogenesis and lymphatic vessel
regeneration in vivo [102, 103]. Given the clinical use of
retinoids for the treatment of inflammatory diseases such as
psoriasis and psoriatic arthritis, one might speculate that
their pro-lymphangiogenic activity might contribute to the
therapeutic effects in these diseases.
Most non-steroidal antiinflammatory drugs (NSAIDs)
inhibit COX-1 and/or COX-2 enzymes which mediate the
biosynthesis of prostaglandins including prostaglandin E2.
Recently, it was found that prostaglandin E2 promotes
lymphangiogenesis by up-regulation of VEGF-C and -D
(Table 1) and that COX inhibitors reduce tumor-induced
lymphangiogenesis [104] and secondary lymphedema
[105]. Moreover, NSAIDs inhibited VEGF-D mediated
Angiogenesis (2014) 17:359–371 365
123
dilation of tumor draining collecting lymphatics [106]. At
present, however, more research is needed to investigate
how these findings might be related to anti-inflammatory
efficacy. Similarly, glucocorticoid treatment reduced lym-
phangiogenesis in a model of chronic infection with M.
pulmonis [107], in cornea inflammation [108, 109] and in
tumor xenografts [110]. However, glucocorticoids might
also have direct activating effects on lymphatic endothelial
cells (our own unpublished results), and hydrocortisone is
routinely added to cultures of LECs. Therefore, future
studies are needed to directly investigate the effects of anti-
inflammatory drugs on lymphatic vessel function, with a
particular focus on fluid drainage and immune cell
interactions.
Anakinra, a recombinant version of the endogeneous IL-
1 scavenger IL-1Ra, and tocilizumab, an IL-6R blocking
antibody, have also been found to affect lymphangiogen-
esis [111, 112]. Both drugs have been approved for the
treatment of rheumatoid arthritis but their effects on lym-
phangiogenesis in inflamed joints need to be investigated.
Importantly, the TNF-a neutralizing antibody infliximab
has been reported to increase lymphangiogenesis in treated
mice suffering from inflammatory arthritis [113]. Since
infliximab is also used for other auto-immune diseases such
as psoriasis and colitis, it will be of great interest to
investigate whether infliximab treatment has similar effects
in those conditions as well, and whether the anti-inflam-
matory activity of infliximab may be at least in part
dependent on its pro-lymphangiogenic activity.
Outlook
The active role of lymphatic vessels in inflammation is well
established today and lymphatic vessels have become the
target for the development of new therapeutic strategies to
treat inflammatory diseases. Thus, we have recently initiated
a screening program, using a three-dimensional LEC
sprouting assay as a read-out [114], to identify new activa-
tors of lymphatic vessel function. Using phenotypic screens
of small molecule chemical libraries as well as natural
extract libraries, we identified a natural extract and defined
molecular compounds that promote lymphatic vessel
drainage in vivo (unpublished data). It will be of great
interest to investigate whether these compounds might also
affect lymphatic vessels under inflammatory conditions.
However, there are currently many unanswered questions
with regard to the functional role of lymphatic vessels in
inflammation. Can we specifically promote certain functions
of lymphatic vessels such as fluid drainage or anti-inflam-
mation, without major effects on lymphangiogenesis? Can
we promote inflammatory lymphatic vessel pumping and
reduce lymphatic hyperpermeability at the same time? Is the
expansion of lymphatic vessels within inflamed tissues and
their draining lymph nodes reversible in human diseases?
What is the detailed functional role of lymph node lym-
phangiogenesis with regard to inflammation and tolerance?
What are the effects of currently used anti-inflammatory
drugs on inflammation-associated lymphangiogenesis and/
or lymphatic drainage function? Thus, future studies are
needed to better understand the molecular mediators and
pathomechanisms regulating lymphatic vessel activation in
inflammation.
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